Abstract
Background: Decreased bone mineral density (BMD) has been associated with the use of tenofovir disoproxil fumarate (TDF) in HIV-infected adults. The data in HIV-infected children are conflicting. The aim of this study was to assess the safety of a TDF-containing antiretroviral (ARV) regimen on BMD in paediatric patients. We report the results of a longitudinal 60-month follow-up study. Methods: A total of 21 vertically HIV-infected Caucasian youths (10 male and 11 female) on ARV treatment containing lamivudine, efavirenz and TDF were enrolled (age range 4.9-17.9 years at baseline). BMD was measured at the lumbar spine and in the whole skeleton by DXA. Bone-specific alkaline phosphatase (BAP) was measured as a bone formation marker and urinary N-telopeptide of type-I collagen (NTx) was measured as a bone resorption index. Results: Baseline mean (±sd) BMD measurements of HIV-infected patients expressed as z-scores were -0.7 (±0.9) for lumbar spine and -0.13 (±1.0) for the whole skeleton. BMD measurements did not change significantly during the 60-month observation period. Both BAP and NTx concentrations were higher than a reference group of controls at baseline and remained unchanged throughout the study. Conclusions: Our data indicate that a TDF-containing regimen does not decrease the BMD of HIV-infected youths.
| Original language | English |
|---|---|
| Pages (from-to) | 1053-1058 |
| Number of pages | 6 |
| Journal | Antiviral Therapy |
| Volume | 15 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2010 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases
Cite this
Tenofovir disoproxil fumarate and bone mineral density : A 60-month longitudinal study in a cohort of HIV-infected youths. / Viganò, Alessandra; Zuccotti, Gian V.; Puzzovio, Maria; Pivetti, Valentina; Zamproni, Ilaria; Cerini, Chiara; Fabiano, Valentina; Giacomet, Vania; Mora, Stefano.
In: Antiviral Therapy, Vol. 15, No. 7, 2010, p. 1053-1058.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tenofovir disoproxil fumarate and bone mineral density
T2 - A 60-month longitudinal study in a cohort of HIV-infected youths
AU - Viganò, Alessandra
AU - Zuccotti, Gian V.
AU - Puzzovio, Maria
AU - Pivetti, Valentina
AU - Zamproni, Ilaria
AU - Cerini, Chiara
AU - Fabiano, Valentina
AU - Giacomet, Vania
AU - Mora, Stefano
PY - 2010
Y1 - 2010
N2 - Background: Decreased bone mineral density (BMD) has been associated with the use of tenofovir disoproxil fumarate (TDF) in HIV-infected adults. The data in HIV-infected children are conflicting. The aim of this study was to assess the safety of a TDF-containing antiretroviral (ARV) regimen on BMD in paediatric patients. We report the results of a longitudinal 60-month follow-up study. Methods: A total of 21 vertically HIV-infected Caucasian youths (10 male and 11 female) on ARV treatment containing lamivudine, efavirenz and TDF were enrolled (age range 4.9-17.9 years at baseline). BMD was measured at the lumbar spine and in the whole skeleton by DXA. Bone-specific alkaline phosphatase (BAP) was measured as a bone formation marker and urinary N-telopeptide of type-I collagen (NTx) was measured as a bone resorption index. Results: Baseline mean (±sd) BMD measurements of HIV-infected patients expressed as z-scores were -0.7 (±0.9) for lumbar spine and -0.13 (±1.0) for the whole skeleton. BMD measurements did not change significantly during the 60-month observation period. Both BAP and NTx concentrations were higher than a reference group of controls at baseline and remained unchanged throughout the study. Conclusions: Our data indicate that a TDF-containing regimen does not decrease the BMD of HIV-infected youths.
AB - Background: Decreased bone mineral density (BMD) has been associated with the use of tenofovir disoproxil fumarate (TDF) in HIV-infected adults. The data in HIV-infected children are conflicting. The aim of this study was to assess the safety of a TDF-containing antiretroviral (ARV) regimen on BMD in paediatric patients. We report the results of a longitudinal 60-month follow-up study. Methods: A total of 21 vertically HIV-infected Caucasian youths (10 male and 11 female) on ARV treatment containing lamivudine, efavirenz and TDF were enrolled (age range 4.9-17.9 years at baseline). BMD was measured at the lumbar spine and in the whole skeleton by DXA. Bone-specific alkaline phosphatase (BAP) was measured as a bone formation marker and urinary N-telopeptide of type-I collagen (NTx) was measured as a bone resorption index. Results: Baseline mean (±sd) BMD measurements of HIV-infected patients expressed as z-scores were -0.7 (±0.9) for lumbar spine and -0.13 (±1.0) for the whole skeleton. BMD measurements did not change significantly during the 60-month observation period. Both BAP and NTx concentrations were higher than a reference group of controls at baseline and remained unchanged throughout the study. Conclusions: Our data indicate that a TDF-containing regimen does not decrease the BMD of HIV-infected youths.
UR - http://www.scopus.com/inward/record.url?scp=78651094152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78651094152&partnerID=8YFLogxK
U2 - 10.3851/IMP1650
DO - 10.3851/IMP1650
M3 - Article
C2 - 21041922
AN - SCOPUS:78651094152
VL - 15
SP - 1053
EP - 1058
JO - Antiviral Therapy
JF - Antiviral Therapy
SN - 1359-6535
IS - 7
ER -